当前位置: X-MOL 学术Cytom. Part B Clin. Cytom. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories
Cytometry Part B: Clinical Cytometry ( IF 2.3 ) Pub Date : 2021-04-29 , DOI: 10.1002/cyto.b.22005
Ulrika Johansson 1 , Kathleen Gallagher 2 , Victoria Burgoyne 1 , Marcela V Maus 2 , Keagan S Casey 2 , Gabrielle G Brini 2 , Matthew J Frigault 2 , Jennifer Y Yam 2 , Nikesh Chavda 3 , Caroline Besley 3 , Sanne Lugthart 3, 4
Affiliation  

Chimeric antigen receptor-modified T-cells targeting CD19 (CAR-T19) are licensed for treating relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. Predicting treatment responses and toxicity (e.g., cytokine release syndrome and neurotoxicity) remains a big challenge. CAR-T19 monitoring could increase our understanding of treatment responses and be of relevance to patient management. A robust method for accurate CAR-T19 detection is therefore extremely desirable.

中文翻译:

外周血和脑脊液中 CAR-T19 细胞的检测:适用于常规诊断实验室的检测

靶向 CD19 (CAR-T19) 的嵌合抗原受体修饰 T 细胞获准用于治疗复发/难治性弥漫性大 B 细胞淋巴瘤和 B 急性淋巴细胞白血病。预测治疗反应和毒性(例如,细胞因子释放综合征和神经毒性)仍然是一个巨大的挑战。CAR-T19监测可以增加我们对治疗反应的理解,并与患者管理相关。因此,非常需要一种用于准确检测 CAR-T19 的稳健方法。
更新日期:2021-04-29
down
wechat
bug